Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy iTeos Therapeutics stock

Own iTeos Therapeutics stock in just a few minutes.

iTeos Therapeutics, Inc is a biotechnology business based in the US. iTeos Therapeutics shares (ITOS) are listed on the NASDAQ and all prices are listed in US Dollars. iTeos Therapeutics employs 62 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in iTeos Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ITOS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

iTeos Therapeutics share price

Use our graph to track the performance of ITOS stocks over time.

iTeos Therapeutics shares at a glance

Information last updated 2021-04-29.
52-week range$17.50 - $47.61
50-day moving average $30.53
200-day moving average $30.94
Wall St. target price$54.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.88

Buy iTeos Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy iTeos Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

iTeos Therapeutics financials

Gross profit TTM $0
Return on assets TTM -14.97%
Return on equity TTM -22.45%
Profit margin 0%
Book value N/A
Market capitalisation $842.4 million

TTM: trailing 12 months

Shorting iTeos Therapeutics shares

There are currently 1.5 million iTeos Therapeutics shares held short by investors – that's known as iTeos Therapeutics's "short interest". This figure is 17.5% up from 1.3 million last month.

There are a few different ways that this level of interest in shorting iTeos Therapeutics shares can be evaluated.

iTeos Therapeutics's "short interest ratio" (SIR)

iTeos Therapeutics's "short interest ratio" (SIR) is the quantity of iTeos Therapeutics shares currently shorted divided by the average quantity of iTeos Therapeutics shares traded daily (recently around 362440.98360656). iTeos Therapeutics's SIR currently stands at 4.27. In other words for every 100,000 iTeos Therapeutics shares traded daily on the market, roughly 4270 shares are currently held short.

However iTeos Therapeutics's short interest can also be evaluated against the total number of iTeos Therapeutics shares, or, against the total number of tradable iTeos Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case iTeos Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 iTeos Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0776% of the tradable shares (for every 100,000 tradable iTeos Therapeutics shares, roughly 78 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against iTeos Therapeutics.

Find out more about how you can short iTeos Therapeutics stock.

iTeos Therapeutics share dividends

We're not expecting iTeos Therapeutics to pay a dividend over the next 12 months.

iTeos Therapeutics overview

Iteos Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site